Aptevo Therapeutics, Inc. (APVO)
1.87
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 16:00
1.80
-0.07
(-3.74%)
After-Hours: 18:09
Aptevo Therapeutics EPS Diluted (Quarterly) : -5.313 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.313 |
| March 31, 2026 | -6.405 |
| December 31, 2025 | -5.911 |
| September 30, 2025 | -40.13 |
| June 30, 2025 | -151.29 |
| March 31, 2025 | -1581.72 |
| December 31, 2024 | -1558.04 |
| September 30, 2024 | -17.89 |
| June 30, 2024 | -61.84 |
| March 31, 2024 | -368.20 |
| December 31, 2023 | -493.63 |
| September 30, 2023 | -819.76 |
| June 30, 2023 | -1996.14 |
| March 31, 2023 | 642.88 |
| December 31, 2022 | -1168.71 |
| September 30, 2022 | -2444.59 |
| June 30, 2022 | 9077.71 |
| March 31, 2022 | -2537.89 |
| December 31, 2021 | -2084.64 |
| September 30, 2021 | -2328.58 |
| June 30, 2021 | -2846.53 |
| March 31, 2021 | -2673.50 |
| Date | Value |
|---|---|
| December 31, 2020 | -2800.09 |
| September 30, 2020 | -3419.86 |
| June 30, 2020 | -3425.90 |
| March 31, 2020 | -5695.85 |
| December 31, 2019 | -31.52M |
| September 30, 2019 | -1.258M |
| June 30, 2019 | -2.426M |
| March 31, 2019 | -4.477M |
| December 31, 2018 | -14188.25 |
| September 30, 2018 | -4.546M |
| June 30, 2018 | -4.774M |
| March 31, 2018 | -5.161M |
| December 31, 2017 | -10463.58 |
| September 30, 2017 | -15636.00 |
| June 30, 2017 | -5.466M |
| March 31, 2017 | -4.630M |
| December 31, 2016 | -6.049M |
| September 30, 2016 | -29.09M |
| June 30, 2016 | -28.95 |
| March 31, 2016 | -14508.93 |
| March 31, 2015 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0749 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.356M |
| Total Expenses (Quarterly) | 6.356M |
| Enterprise Value | -2.920M |
| Earnings Yield | -3.09K% |
| Normalized Earnings Yield | -3088.92 |